- Home
- Products
- Customized ADCs
- ERBB2
- Anti-ERBB2 (trastuzumab)-AcLys-β-Ala-MMAD ADC
Anti-ERBB2 (trastuzumab)-AcLys-β-Ala-MMAD ADC (CAT#: ADC-W-634)
This ADC product is comprised of an engineerd anti-ERBB2 antibody (trastuzumab with LLQGG tag at Fc) conjugated via a AcLys-β-Ala linker to MMAD. The MMAD is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAD binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- ERBB2
- Alternative Names
- ERBB2; erb-b2 receptor tyrosine kinase 2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; receptor tyrosine-protein kinase erbB-2; herstatin; p185erbB2; proto-oncogene Neu; c-erb B2/neu protein; proto-oncogene c-ErbB-2; metastatic lymph node gene 1
- Target Entrez Gene ID
- 2064
- Target UniProt ID
- P04626
- Overview
- This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
- Overview
- Engineerd Trastuzumab with LLQGG tag at Fc
- Generic name
- trastuzumab
- Host animal
- Mouse
- Species Reactivity
- Human
- Name
- AcLys-β-ala
- Name
- MMAD (monomethyl auristatin D)
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD79b (clone huMA79b.v28)-Mc-VC-PABC-MMAE ADC (CAT#: ADC-W-029)
- Anti-GD2 (Dinutuximab)-MC-MMAF ADC (CAT#: ADC-W-2008)
- Anti-CD5 (Telimomab aritox)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-936)
- Anti-APP (Gantenerumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-683)
- Anti-TNF (Afelimomab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1853)
- Anti-EGFR (Panitumumab)-SPDB-DM4 ADC (CAT#: ADC-W-1041)
- Anti-CSF2 (Lenzilumab)-SPDB-DM4 ADC (CAT#: ADC-W-2307)
- Anti-HLA-DRB1 (Apolizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1207)
- Anti-CEACAM8 (Besilesomab)-MC-MMAF ADC (CAT#: ADC-W-2206)
- Anti-MUC1 (Clivatuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-1617)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-634. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-1110 | Anti-ERBB2 (Margetuximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2595 | Anti-ERBB2 (Trastuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-1112 | Anti-ERBB2 (Pertuzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2596 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-116 | Anti-ERBB2 (Trastuzumab)-Gly5-modified DM1 ADC | C-terminal GS (glycine-serine) linker | Gly5-modified DM1 (Gly5-modified N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-290 | Anti-TACSTD2 (clone 7E6)-AcLys-VC-PABC-MMAD ADC | AcLys-VC- PABC (Acetyl-lysine-valine-citrulline-p-aminobenzyloxycarbonyl) | MMAD (monomethyl auristatin D) |
ADC-W-408 | Anti-ERBB2 (Trastuzumab)-MMAD ADC | Non-Cleavable hydroxyl amino PEG linker | MMAD (monomethyl auristatin D) |
ADC-W-166 | Anti-TPBG (V422C)-VC-MMAD ADC | VC (valine-citrulline) | MMAD (monomethyl auristatin D) |
ADC-W-165 | Anti-TPBG (L398C)-VC-MMAD ADC | VC (valine-citrulline) | MMAD (monomethyl auristatin D) |
ADC-W-631 | Anti-ERBB2 (trastuzumab)-AcLys-VC-PABC-MMAD ADC | AcLys-VC-PABC (Acetyl-lysine-valine-citrulline-p-aminobenzyloxycarbonyl) | MMAD (monomethyl auristatin D) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.